Genetic, immunological and clinical assessment of isolated chronic recalcitrant dermatophytosis: a prospective study
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljaf269 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Eran Galili und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Tinea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Chronic recalcitrant dermatophyte infection (CRDI) remains poorly understood, with limited research on its genetic, immunological and treatment aspects.
Objectives
To investigate the genetic and immunological profiles, clinical characteristics and treatment outcomes in otherwise healthy patients with CRDI.
Methods
This was a prospective study of patients with isolated superficial dermatophyte infections persisting for > 5 years and refractory to at least three oral antifungal agents. Whole-exome sequencing, interleukin (IL)-17 quantification and lymphocyte subset analysis were performed.
Results
Of 5910 patients with superficial cutaneous fungal infections, 11 (10 men; 91%) with a mean (SD) disease duration of 26.4 (8.7) years were included in this study. All patients presented with extensive dermatophytosis, involving a mean (SD) of 5.6 (1.4) skin and nail sites. Immune alterations were identified in 55% (n = 6/11) of the patients, including three with monogenic immunodeficiency mutations (CARD9 and FOXN1), one with acquired immunodeficiency (Good syndrome) and two with isolated IL-17 deficiencies. Most patients (n = 10/11) showed a partial clinical response to continuous oral antifungal therapy, while only one patient remained a complete responder after discontinuing treatment.
Conclusions
CRDI is a rare condition in patients with superficial cutaneous fungal infections. Genetic and immunological evaluation for immunodeficiency should be considered in patients with CRDI. Management may require prolonged or lifelong oral antifungal therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Dermatology, Sheba Medical Center, Tel HaShomer, Israel.
- Pediatric Department A and Immunology Service, Jeffrey Modell Foundation Center, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel HaShomer, Israel.
- Clinical Microbiology, Sheba Medical Center, Ramat-Gan, Israel.
- The Genomic Unit, Sheba Cancer Research Center, Sheba Medical Center, Tel HaShomer, Israel.
ORCID-Profile: Eran Galili, Aviv Barzilai, Atar Lev, Sharon Amit, Ortal Barel, Irit Lubitz, Anna Lyakhovitsky, Raz Somech, Avner Shemer
Zitieren
APA
Galili, E., Barzilai, A., Lev, A., Amit, S., Barel, O., Lubitz, I., Gazit, Z., Lyakhovitsky, A., Somech, R., & Shemer, A. (2025). Genetic, immunological and clinical assessment of isolated chronic recalcitrant dermatophytosis: a prospective study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf269
Vancouver
Galili E, Barzilai A, Lev A, Amit S, Barel O, Lubitz I, et al. Genetic, immunological and clinical assessment of isolated chronic recalcitrant dermatophytosis: a prospective study. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf269
BibTeX
@article{Galili2025,
author = {Galili, Eran and Barzilai, Aviv and Lev, Atar and Amit, Sharon and Barel, Ortal and Lubitz, Irit and Gazit, Zeala and Lyakhovitsky, Anna and Somech, Raz and Shemer, Avner},
title = {Genetic, immunological and clinical assessment of isolated chronic recalcitrant dermatophytosis: a prospective study},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljaf269}
}
EUVIMED